Paper Details
- Home
- Paper Details
[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
Author: FukumaEisuke, HaruyamaYurie, KoshidaYoshitomo, NashimotoMika, SakamotoNaomi, SasakiAkiko, TsunodaYuko
Original Abstract of the Article :
In 2018, olaparib, a PARP inhibitor, was approved for the treatment of BRCA1/2 gene-mutation positive and HER2-negative inoperable and recurrent breast cancer; BRCA1/2 gene testing was also listed as a companion diagnostics. Here, we identified microRNAs(miRNAs) expressed after treatment with olapar...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://pubmed.ncbi.nlm.nih.gov/33468723
データ提供：米国国立医学図書館（NLM）
PARP-1 Inhibition and Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a particularly aggressive form of breast cancer characterized by the lack of expression of estrogen receptors, progesterone receptors, and HER2. This study explores the potential of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in treating TNBC cells with a BRCA1 mutation. The researchers investigate the impact of olaparib on the expression of microRNAs (miRNAs), small non-coding RNA molecules involved in gene regulation, and examine the effect of combining olaparib with gemcitabine, a chemotherapeutic agent, on TNBC cells.
Targeting PARP-1 in TNBC
This study highlights the potential of olaparib, a PARP inhibitor, as a therapeutic strategy for treating TNBC cells with a BRCA1 mutation. The researchers observed significant changes in miRNA expression in TNBC cells treated with olaparib, suggesting a potential role for PARP inhibition in modulating gene regulation. The study also demonstrates that combining olaparib with gemcitabine may enhance the sensitivity of TNBC cells to chemotherapy, potentially improving treatment outcomes.
Improving Treatment Strategies for TNBC
This study provides valuable insights into the potential of PARP inhibitors, specifically olaparib, in treating TNBC cells with a BRCA1 mutation. The researchers' findings suggest a potential role for olaparib in modulating gene regulation through miRNA expression and enhancing the effectiveness of chemotherapy. This research could lead to improved treatment strategies for TNBC, a particularly challenging form of breast cancer. Just like a camel can survive in the desert by finding sources of water, healthcare professionals are continuously seeking innovative treatments for TNBC.
Dr. Camel's Conclusion
This study explores the potential of olaparib, a PARP inhibitor, in treating TNBC cells with a BRCA1 mutation. The researchers observed significant changes in miRNA expression in TNBC cells treated with olaparib, suggesting a potential role for PARP inhibition in modulating gene regulation. The study also demonstrates that combining olaparib with gemcitabine may enhance the sensitivity of TNBC cells to chemotherapy, potentially improving treatment outcomes. This research could lead to improved treatment strategies for TNBC, a particularly challenging form of breast cancer.
Date :
- Date Completed 2021-01-21
- Date Revised 2021-01-21
Related Literature
Japanese
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.